Skip to main content

Table 1 Baseline clinical characteristics of patients with different chemo-mobilization regimens (n = 128)

From: Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma

Variables Cyclophosphamide
(n = 65)
Etoposide
(n = 63)
P-value
Median age, year (range) 55.0 (39 ~  64) 57.0 (34 ~  65) 0.359
Male, n (%) 39 (60.0%) 36 (57.1%) 0.743
Ig type, n (%)    0.173
 IgG 35 (53.8%) 44 (69.8%)  
 IgA 8 (12.3%) 6 (9.5%)  
 IgM 1 (1.5%) 1 (1.6%)  
 Light chain only 21 (32.3%) 11 (17.5%)  
ISS, n (%)    0.356
 I 22 (33.8%) 15 (23.8%)  
 II 21 (32.3%) 27 (42.9%)  
 III 22 (33.8%) 21 (33.3%)  
ECOG PS ≥ 2, n (%) 6 (9.2%) 2 (3.2%) 0.274
LDH > (1 × ULN), n (%) 7 (10.9%) 11 (17.5%) 0.292
Median BM plasma cells, %, range 35.0 (4.0 ~  90.0) 27.0 (0.9 ~  95.8) 0.068
Median lymphocyte count, (× 109/L), range 2.00 (0.4 ~  6.23) 2.19 (0.57 ~  4.78) 0.340
Serum creatinine ≥2 mg/dL, n (%) 13 (20.3%) 8 (12.7%) 0.340
Median platelet count (× 109/L), range 201 (48 ~  393) 206 (63 ~  509) 0.802
Median serum Hb, g/dL 9.8 (4.9 ~  15.3) 10.0 (6.2 ~  15.4) 0.577
Median time to mobilization, months (range) 4.67 (2.53 ~  6.80) 3.88 (2.43 ~  6.18) < 0.001
Frontline treatment, n (%)
 Thalidomide-based 59 (81.9%) 20 (31.3%)  
 Bortezomib-based 7 (9.7%) 14 (21.9%)  
 Bortezomib+Thalidomide 0 (0.0%) 29 (45.3%)  
 Conventional chemotherapy 6 (8.3%) 1 (1.6%)  
Median prior treatment cycle, n, range 4 (3 ~  7) 4 (3 ~  6) 0.056
Radiotherapy (spine), n (%) 18 (27.7%) 15 (23.8%) 0.616
Disease status at mobilization    0.359
 CR 12 (18.5%) 16 (25.4%)  
 VGPR 14 (21.5%) 7 (11.1%)  
 PR 36 (55.4%) 38 (60.3%)  
 SD 3 (4.6%) 2 (3.2%)  
 PD 0 (0.0%) 0 (0.0%)  
  1. Abbreviations: N number, ISS international staging system, ECOG Eastern Cooperative Oncology Group, PS performance status, LDH lactate dehydrogenase, ULN upper limit of normal value, BM bone marrow, Hb hemoglobin, CR complete response, VGPR very good partial response, PR partial response, SD stable disease, PD progressive disease
\